摘要
目的 探讨基质金属蛋白酶(MMP)-9在前列腺癌(PCa)组织中的表达及其临床意义.方法 采用免疫组织化学方法检测60例前列腺疾病患者组织中MMP-9的表达,60例患者中PCa 30例:Ⅰ期4例,Ⅱ期13例,Ⅲ期10例,Ⅳ期3例,良性前列腺增生(BPH) 30例.对PCa组织切片进行TNM分期,观察.结果 MMP-9在PCa组中阳性率为63.3% (19/30),BPH组为13.3%(4/30),两者差异有统计学意义(P <0.05);MMP-9阳性表达与PCa临床分期明显相关.转移组(Ⅲ+Ⅳ期)MMP-9阳性率为76.9%(10/13),非转移组(Ⅰ+Ⅱ期)为52.9%(9/17),两者差异有统计学意义(P<0.01).MMP-9阳性表达与肿瘤转移有相关.结论 MMP-9阳性表达提示患者预后差,可作为判断PCa浸润转移的指标.
Objective To investigate the expression of matrix metalloproteinase (MMP)-9 in prostate cancer tissue and its clinical significance.Methods Sixty patients with prostate diseases,including 30 cases of prostate cancer:stage Ⅰ in 4 cases,stage Ⅱ in 13 cases,stage Ⅲ in 10 cases and stage Ⅳ in 3 cases,and 30 cases of benign prostatic hyperplasia (BPH).Thirty cases of PCa were observed based on the hematoxylin eosin staining for TNM staging.Results The positive rate of MMP-9 was 63.3% (19/30) in prostate cancer group,and 13.3 % (4/30) in BPH group (P < 0.05).There was a close correlation between MMP-9 expression and clinical staging of prostate cancer.In the metastasis groups (stages Ⅲ and Ⅳ),MMP-9 positive rate was 76.9% (10/13),and in the non-metastasis group (stages Ⅰ and Ⅱ) that was 52.9% (9/17) (P <0.01).There was a close correlation between MMP-9 expression and tumor metastasis.Conclusion MMP-9 positive expression was a hint of poor prognosis of prostate cancer patients,which can be used as an indicator of prostate cancer metastasis.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2014年第8期1832-1833,共2页
Chinese Journal of Experimental Surgery